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Background: At the start of the COVID-19 pandemic, guidance was needed more
than ever to direct frontline healthcare and national containment strategies. Rigorous
guidance based on robust research was compromised by the emergence of the pan-
demic and the urgency of need for guidance. Rather than aiming to “get guidance
right”, guidance developers needed to “get guidance right now”.
Aim: To examine how guidance developers have responded to the need for credible
guidance at the start of the COVID-19 pandemic.
Methods: An exploratory mixed-methods study was conducted among guidance
developers. A web-based survey and follow-up interviews were used to examine the
most pertinent challenges in developing COVID-19 guidance, strategies used to
address these, and perspectives on the implications of the COVID-19 pandemic on
future guidance development.
Results: The survey was completed by 46 guidance developers. Survey findings
showed that conventional methods of guidance development were largely unsuited for
COVID-19 guidance, with 80% (n = 37) of respondents resorting to other methods.
From the survey and five follow-up interviews, two themes were identified to bolster
the credibility of guidance in a setting of extreme uncertainty: (1) strengthening end-
user involvement and (2) conjoining evidence review and recommendation formulation.
70% (n = 32) of survey respondents foresaw possible changes in future guidance pro-
duction, most notably shortening development time, by reconsidering how to balance
between rigour and speed for different types of questions.
Conclusion: “Getting guidance right” and “getting guidance right now” are not oppo-
sites, rather uncertainties are always part of guidance development and require guid-
ance developers to balance scientific robustness with usability, acceptability, adequacy
and contingency. This crisis points to the need to acknowledge uncertainties of scien-
tific evidence more explicitly and points to mechanisms to live with such uncertainty,
thus extending guidance development methods and processes more widely.
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1 | INTRODUCTION
Throughout the COVID-19 pandemic, there has been a pressing need
for reliable guidance, ranging from clinical guidance for frontline
healthcare to public health guidance for national containment strate-
gies. Guidance was needed to direct clinical care, ensure fair distribu-
tion of resources1,2 and support public adherence to government
policies.3 Whereas guidance is often produced over a longer period of
time,* guidance developers were faced with the task of evaluating a
fleeting and complex body of knowledge within weeks or days.4,5 This
posed a challenge to guidance developing bodies (e.g., WHO, NICE,
SAGE, NIPH, CDC) worldwide, since methods for developing guidance
have increasingly emphasized basing recommendations on rigorously
appraised6 frequency-type evidence (such as systematic reviews of
randomized controlled trials).7 Frequency-type reasoning builds on
the idea that events (e.g., response to a certain intervention) we often
observe give the best prediction for future events, which would make
frequently observed events count as the “best research evidence” to
make causal inferences regarding the intervention in question. The
prioritization of frequency-type reasoning no longer worked in the
setting of this pandemic; a time of great uncertainty and urgency.7
Due to epistemic uncertainty, in which knowledge or understanding is
insufficient (see Reference [8], p. 507), prevailing grading methods
such as GRADE that predominantly focus on evidence that is statisti-
cally reliable and privileges high internal validity,9 often result in weak
recommendations for strongly pressing issues.† Guidance institutions
tried to streamline guidance development but found the emergence
of a new disease and the urgency of need compromised the require-
ment for basing recommendations on prevailing standards of robust
“high quality” research evidence.10 Instead, guidance developers
needed to rely on other types of knowledge,11 including observational
studies,11 mechanistic studies5,12 and indirect evidence on the effects
on transmission of other viruses in non-pandemic conditions.13 What
is more, the urgency for guidance meant that developers could no lon-
ger aim to “get things right” but had to “get things right now”. The
style of reasoning became one of “taking care while the uncertain
future unfolds” (see Reference [7], p. 89). Guidance production in this
context could now better be described as “know-now”: a form of
knowing “used to interpret new situations, to establish what might be
the problem, and how [one] could act” (see Reference [14], p. 80).
Greenhalgh notes that the logic of evidence-based medicine
remains useful in some aspects of outbreak guidance (e.g., studying
drug and vaccine efficacy), but that additional methods are needed on
how to manage epistemic uncertainty, the unpredictability of events,15
but also, the incorporation of patient's and public's values in the formu-
lation of recommendations.‡ Whereas “political decision-making seems
to have become technocratic backed by scientific signals” (see Refer-
ence [16], p. 614), it has shown that simply “following the science”
becomes problematic when it neglects other areas of science
(e.g., economics, psychology, sociology, behavioural science) and the
diversity of impacts on patients and society.17 Whereas EBM provides
detailed methods for appraising and including population-level research
in guidance development, too narrow a focus on population-based
research devalues the mechanistic and experiential knowledge8—which
are often among the few sources of knowledge in the early phases of a
health crisis. In contrast to the fine-grained assessment tools that exist
for evidence that is high up in the frequentist “evidence hierarchy”, the
COVID-19 pandemic has shown that sustaining those prevailing stan-
dards of evidence would result in providing no guidance—a luxury few
guidance producing bodies felt they could permit themselves. So how
did developers cope in the meantime: how did guidance developers act
while experiencing a “failure of routines?” (see Reference [14], p. 80).
How did they substantiate recommendations based on best knowledge
available? How did they accommodate uncertainty in guidance? And
what consequences do they anticipate, based on their experience with
pandemic guidance production, for guidance production post
COVID-19?
This study reports on the practices of guidance development dur-
ing the COVID-19 pandemic to illustrate how developers have
responded to the need for credible guidance, in the face of uncertain
knowledge and extreme time pressure. Drawing on those practices
and experiences, we reflect on lessons that can be drawn for the
future of guidance production.
2 | METHODS
2.1 | Study design
The study involved two phases: a web-based survey and qualitative
follow-up interviews. The Institutional Review Board of the Faculty of
Science (BETHCIE) of the Vrije Universiteit Amsterdam approved this
research as exempt.
2.2 | Survey
The survey instrument (Supporting information) was drafted by M.M.,
J.R. and T.Z.J. Given the timing of survey administration in May 2020,
during the aftermath of the first pandemic wave, we opted for a
“rapid survey” design consisting of 12 items, taking into account that
many developers were deeply involved in the hectic work of guidance
production, while this was also a crucial time to capture their experi-
ences. Eight closed-ended questions inquired about knowledge sources
used to develop COVID-19 guidance and methods used for rapid
knowledge appraisal and synthesis. Respondents could add comments
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to clarify their answer. In addition, four open-ended survey questions
inquired about the challenges in developing COVID-19 guidance, strate-
gies used to address these and perspectives on the implications of the
COVID-19 pandemic on future guidance development. F.M., S.W.,
B.S. and F.F. reviewed and revised the survey. The survey was sent out
for external review to members of the Guidelines International Network
(GIN), with one member providing comments. In May 2020, the survey
was sent to 1333 members of GIN via email. The rapid survey was car-
ried out among the members of the Guidelines International Network,
since they comprise a broad group of guideline developers from around
the world. Participants were informed about the purpose of the study
and the anonymity of all study participants was guaranteed. Consent
was confirmed upon agreement to participate in this study.
The survey consisted of closed questions that generated nominal
data, entered into SPSS Statistics (version 26) software and analysed
using descriptive statistics. Transcripts from open-ended survey ques-
tions were analysed with a grounded theory approach in which codes,
categories and themes that emerged from the data were identified by
using the ATLAS.ti software. Coding was conducted by two indepen-
dent reviewers (M.M. and J.R.) based on the interview protocol and
research questions. The most salient codes and relationships between
codes were identified and aggregated into descriptive themes, using
thematic synthesis.
2.3 | Interviews
Trained research interviewers (M.M. and J.R.) conducted the semi-
structured follow-up interviews using Zoom videoconferencing
between June and August 2020 to further understand challenges
and changes in guidance production. We invited survey respondents
who indicated willingness to participate in follow-up interviews via
email (4 participated, 4 declined participation, 3 did not respond,
1 was not eligible). People who declined indicated being too busy to
participate. Furthermore, one interview participant was recruited
using snowballing as a supplementary approach to the main recruit-
ment method. The participants and the interviewers did not have
any contact before the interview other than to set the appointment.
Participants were contacted via email and were informed that they
were going to participate in a 45-minute interview about their expe-
riences with developing COVID-19 guidance. Anonymity was
guaranteed and interviewees were asked to agree to the terms of
the interview verbally.
The interview guide (Supporting information) was developed on
the basis of the survey results. The guide inquired about how the chal-
lenges of the COVID-19 pandemic affected guidance procedures. Prob-
ing questions were used to get a better sense of the changes in
practice that were identified through the survey. Finally, participants
were asked to reflect on the implications of the COVID-19 pandemic
on future guidance development. With participant consent, interviews
were audio recorded and transcribed verbatim. Analysis was performed
following the same methods as for qualitative analysis of the survey.
3 | RESULTS
The survey was completed by 76 members from 26 countries, of
whom 46 members were currently involved in developing COVID-19
guidance. Demographic characteristics are summarized in Table 1.
Follow-up interviews were conducted with two developers/information
specialists and three guidance department directors.
TABLE 1 Survey respondent characteristics (n = 46)
Characteristics Dataa
Specialty (MC)
Chronic care 35% (16)
Emergency care 15% (7)
Long-term care 9% (4)
Mental healthcare 17% (8)
Nursing 11% (5)
Occupational health 9% (4)
Oncology 13% (6)
Paediatrics 20% (9)
Primary care 28% (13)
Public health 20% (9)
Surgery 9% (4)
All of the above 13% (6)
Experience in guidance production
<2 years 11% (5)
2–5 years 17% (8)
5–10 years 11% (5)
10–20 years 37% (17)
>20 years 24% (11)
Guidance developed for
National use 65% (30)
International use 15% (7)






United States of America 39% (18)
Central and South America 2% (1)
Standardized methodology used within institutions (MC)
National standard for guideline development 43% (20)
Inhouse developed guideline development
methodology
41% (19)
GRADE methodology 33% (15)
Other 15% (7)
aData are the number (percentage) of survey respondents. Percentages
may not total to 100 owing to rounding and/or multiple-choice
questions (MC).
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3.1 | Knowledge appraisal in a setting of limited
evidence
The survey inquired about knowledge sources used to develop
COVID-19 guidance and methods used for rapid knowledge appraisal
and synthesis. Conventional methods of guidance development were
largely unsuited to the production of recommendations in this new
context, with 80% (n = 37) of survey respondents resorting to differ-
ent procedures for appraising and including knowledge. In the com-
ments section, respondents described that conventional methods
were too lengthy, too reliant on systematic reviews of empirical
research evidence and poorly suited to the appraisal of other types
of knowledge. Conventional methods were also not designed to
respond rapidly to new knowledge; respondents highlighted flexibil-
ity as crucial, producing rapid updates to guidance, occasionally
many times. Figure 1 shows that developers often relied on expert
opinion (76.6%, n = 36) and other sources of information otherwise
considered as being at too high a risk of bias on which to base
recommendations.
3.2 | Responding to the need for credible guidance
in COVID-19 times
This section reports on findings from the survey and the interviews
regarding the greatest challenges in developing COVID-19 guidance
and strategies used to address these. Findings indicated that devel-
opers were working with a very limited number of studies, mostly
with small study samples and concomitant risk of bias. In addition,
many experts, who usually can delegate parts of the everyday clinical
work to more junior staff and dedicate time to serve on guidance
working groups that evaluate evidence and develop recommenda-
tions, were extremely busy with clinical duties at the frontline. One
respondent notes that “knowledge regarding diagnosis, treatment was
evolving rapidly [in the field], while the evidence base is still limited”. In
addition, other respondents reported lacking rigorous methods to
appraise and include these wide-ranging types of knowledge to come
to robust guidance in the absence of frequentist (RCT-based) evi-
dence. Guidance institutions were confronted with the challenge of
maintaining their reputation, while the rapidly changing knowledge
about COVID-19 and its clinical management meant that guidance
was often only valid for a short time - weeks, days (or even hours). As
one survey respondent described, the most pressing challenge was
the development of: “credible guidelines that folks want to adhere to,
[but] that are stale a week after they are published”.
Based on our analysis of responses, we identified two strategies
in guidance development to cope with these challenges. The urgency
of need and the rapidly changing evidence base worked as catalysts
to strengthen two mechanisms for bolstering the credibility of guid-
ance: (1) Pre- and post-publication end-user involvement and (2) con-
joining evidence review and recommendation formulation.
3.3 | Pre- and post-publication end-user
involvement
Developers reported that the conventional phases of guideline devel-
opment were followed, albeit shortened, as there was simply so little
relevant evidence that was sufficiently robust to review. A survey
respondent described: “Rapid rate of publication of findings, lack of rig-
our of most published findings, many papers are based on limited sample
sizes (..) and/or on other countries' data with different patient demo-
graphics and resources”. The poor quality of evidence and the need to
translate evidence to local contexts underlined the importance of
expert input during guidance development and tracking the validity of
published guidance in practice.
Getting diverse clinical input into the guidance working groups
was reported by three interviewees as one of the biggest challenges.
One interviewee described that their institution tried to make working
groups as diverse as possible, recognizing that guidance was largely
based on consensus—the credibility of which depends heavily on the
representation of diverse views. In addition, feedback mechanisms
were strengthened to move more towards the concept of living guide-
lines to allow developers to provide guidance that was “good enough”
to respond to immediate crises while keeping closely in touch with
practice and changes in knowledge. For example, an interviewee
described designated COVID-19 channels through which clinicians
could submit feedback and requests for guidance.
F IGURE 1 Knowledge types used for
COVID-19 guidance. Figure 1 indicates
what knowledge types respondents (% of
n = 46) used for developing COVID-19
guidance. Editorials came up as a new
category. Many journals have published
editorials to allow for swift publication of
experiences with COVID-19. In addition,
the extrapolation of evidence from
comparable diseases was added as a
source of knowledge
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[After the first wave we] build in this 'living guideline'
concept and that helped us with the speed of develop-
ment, because what we could say to the teams and (…)
the clinicians: “don't expect perfect”. The issue here is
having something that is good enough for what was
clearly an emergency (…) [building in] a rapid update in
the process so as more evidence emerges, we could
tweak and change (…) and having mechanisms for clini-
cians to feedback (Interviewee 4).
These feedback loops were based on principles of transparency
and flexibility in order to develop credible guidance in a context of
limited and uncertain knowledge.
The need to speed up the processes of collating evidence and
developing guidance thus forced developers to make pragmatic
choices. Where mechanisms for feedback by clinicians were installed
rapidly, similar involvement of patients was largely abandoned in the
early stages of the pandemic. An interviewee mentioned for example
that patients' levels of involvement dropped drastically and later were
somewhat restored. “At the very beginning there was no patient involve-
ment at all. We're now at a stage where there is a lot of patient involve-
ment but not at the same level as before”. The quote illustrates how
initial choices to bolster pragmatism were later revised to rebalance
considerations of rigour and pragmatism. Furthermore, where feed-
back by clinicians was instantly seen as central to creating living
guidelines in times of uncertainty, the same did not apply to patients.
3.4 | Conjoining evidence review and
recommendation formulation
In addition to fostering close connections between guidance institu-
tions and end users, teams working within guidance institutions also
sought closer collaboration. As an interviewee described, separate
teams whose main activities were either evidence surveillance or
guidance development were joined to allow for rapid updating of
COVID-19 guidance.
[Normally] we have a surveillance team that is continu-
ally trawling the evidence [and] topic experts [judging]
“we should or should not update the guideline” (..) with
Covid we're bringing those closer together or making
them concurrent because of the repetitiveness of the
evidence changes and the need to be as up to date as
we can (interviewee 4).
Another interviewee described how evidence appraisal teams
(systematic reviewers) became more closely involved in formulat-
ing recommendations, removing boundaries between activities
traditionally performed separately by systematic reviewers and
developers with topic expertise. The interviewee described how
their institution had tried for years to shift the culture and bring
the work of systematic reviewers and guidance developers closer.
This shift was catalysed by the pandemic and the need for faster
guidance production. Systematic reviewers became closer to the
translation of evidence into practice recommendations, while rely-
ing more heavily on sources of evidence at higher risk of bias
than conventionally accepted and on consensus. This led to a bet-
ter understanding and more respect for the work of different
teams.
3.5 | Future perspectives
This section provides an overview of survey and interview findings
regarding possible future implications of the COVID-19 pandemic
on the future of guidance production beyond the pandemic. The
vast majority of survey respondents (70%, n = 37) thought it possi-
ble that the failure of existing routines and the new practices that
emerged while developing guidance in response to the pandemic
could lead to future changes in conventional guidance develop-
ment, with 44% (n = 20) of respondents actually expecting this
change to occur. The remaining 30% (n = 14) considered the
COVID-19 pandemic to be an exceptional situation and emphasized
the need to return to traditional, “gold standard” procedures as
soon as possible.
The majority of respondents expected or hoped that this
approach to guidance development might influence future guidance
production, most notably by shortening development time. An inter-
viewee said that developers, systematic reviewers and end-users need
to be willing to acknowledge the inevitable uncertainty and the asso-
ciated risks of this in all guidance. Guidance recommendations are
developed primarily to guide clinical, public health or social action and
to minimize risk to patients and the public. Nonetheless, an approach
to guidance that is too risk-averse and prolongs development is in
itself a huge risk.
Another interviewee noted that it is currently difficult to deter-
mine when conventional methods for maximizing the quality of the
research evidence are needed, and when other mechanisms to pro-
duce credible guidance can be used. They called for a discussion
within the guidance community to develop better criteria to strike the
right balance between the two modes of guidance production.
In cases of poor evidence, the superiority of GRADE as
opposed to other, less extensive, methods for grading,
is not straightforward (…) especially when you know in
advance that there is no good quality evidence. We
need to design criteria regarding when to resort to
GRADE or not (interviewee 1).
This quote highlights the need to explain uncertainties inherent in
guidance development. The need to identify when it is wise to resort to
GRADE or not is also supported by other studies. Mercuri and Gafni18
have for example argued that although transparency about weighing
the evidence is considered one of the main advantages of using
GRADE, in practice choices often remain insufficiently substantiated
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and explained, leaving considerable space for interpretation regarding
the operationalisation of the GRADE framework. One survey respon-
dent remarked: “For all the wrong reasons, I am happy that at last our
greatest critics are now faced by the same problems we had to deal with
all of our careers”. The 'critics' referred to are those who argue that
guidance should rely only on “high quality” evidence, regardless of the
question being asked. This respondent was expecting the COVID-19
pandemic to challenge such attitudes and help find ways to include
other sources of knowledge in guidance development.
4 | DISCUSSION
This study describes how guidance developers coped with the very
specific problem of extreme knowledge uncertainty and urgent time
pressures during the COVID-19 pandemic. Some respondents consid-
ered COVID-19 guidance the “messy exception to the gold standard”.
However, most developers thought that the COVID-19 outbreak
uncovered real anxieties about the complete absence of empirical evi-
dence while working with tools that did not help to deal with such
major uncertainties. The development of methods for ensuring the
statistical reliability and internal validity of the evidence,9 has been an
important driving force of the EBM movement19 to safeguard the
trustworthiness of guidance. The quality of the evidence in this con-
text is equated with the level of statistical confidence in study out-
comes.20 Baigrie and Mercuri9 posit that this tradition insufficiently
acknowledges that what is considered “best available research evi-
dence” may be different from field to field, or question to question.
The authors describe that the prioritization of the “goodness” of evi-
dence in evidence-based medicine defined as preferencing study
designs that provide the most reliable/valid basis for studying causa-
tion, insufficiently acknowledges that the goodness of evidence and
the relevance of the evidence for the question at hand are distinct
criteria. Perillat and Baigrie5 note that the evaluation of methodologi-
cal rigour is an essential element for supporting evidence-based
decision-making, but also argue that other criteria including relevance,
feasibility, adaptability and acceptability should be taken into account
- considerations that may be better addressed using different kinds of
studies. Hence, “best research evidence” is not merely defined by the
(statistical) “confidence” in the evidence, but also needs to speak to
the situation for which guidance is being developed and the
objective(s) of the guidance. In an opinion piece entitled “controversial
policies on COVID-19 stem from a deeply rooted view of evidence”21
Sager analyses how maintaining high evidence-thresholds for COVID-
19 policies in Sweden, resulted in guidance that ironically bears close
resemblance to those of the anti-scientific approach of populists like
Donald Trump: no lockdown or mask mandates in the pandemic's first
6 months. Sager notes that the risk of such a technocratic approach is
that “a lack of positive evidence can easily be misread as negative evi-
dence” and that inflexible evidence thresholds “ignore the merits of a
broader approach to evidence”.21 Guidance developers in other loca-
tions almost invariably ended up abandoning prevailing standards of
evidence for guidance development as decisions had to be made even
without gold-standard evidence. This study's findings describe which
mechanisms guidance developers mobilized to balance “goodness” and
“relevance”, a process we paraphrase as shifting the focus from “get-
ting guidance right” to “getting guidance right now”.
By studying the practices of guidance developers during the pan-
demic, we have identified two changes in their working processes.
First, the COVID-19 outbreak highlights the need to strengthen
expert feedback before and after publication to keep guidance con-
nected and relevant in case of a changing knowledge base,22 the
emergence of crucial first-hand clinical experience and in a setting
where the political and social acceptability of public health guidance
cannot be drawn from having used rigid epistemic criteria. Further-
more, the involvement of end-users helps to ensure that questions
are matched to the most pertinent needs from the field.5 Second,
linking more closely the evidence appraisal and recommendation for-
mulation can short-circuit the usual, more lengthy guideline develop-
ment processes. The focus is on publishing rapid guidance that,
supported by pragmatic mechanisms, could be updated as new insights
emerged, rather than guidance intended to be used for a number of
years. This allows the focus to shift from getting recommendations that
are based on the statistical “goodness” of evidence to getting those
that are predominantly “relevant”; that is, less-than-perfect but when
needed. Through these mechanisms developers avoid needing to
choose between harms from issuing incorrect or incomplete guidance
and the ethical risk of issuing no guidance at all. These mechanisms
offer ways to manage epistemic uncertainty and unpredictability, by
balancing scientific robustness with usability, acceptability, adequacy23
and contingency of the guidance22 in more explicit ways.
A strength of this study is that the timing of the survey adminis-
tration coincided with the aftermath of the first pandemic wave, mak-
ing the findings particularly timely and pertinent. In addition, the
exploratory mixed-methods design allowed us to gain a better under-
standing of the challenges reported in the survey and discuss why par-
ticipants expected changes in future guidance production.
A limitation of this study was that due to the timing and pertinence,
we needed to adjust to the hectic situations many developers found
themselves in. Given these circumstances, we opted for a “rapid survey”
design consisting of limited number of items. Although the survey
instrument was reviewed and tested by three researchers experienced
in the field of guidance development, it was not feasible to fully validate
it. In addition, since we wanted to do the interviews while memories of
guidance development were still recent and current, we were able to
recruit no more than the limited number of five respondents for the
follow-up interviews. These study design choices lowered methodologi-
cal rigour, but enabled us to capture aspects of the worldwide experi-
ences regarding guidance development practices during the first
pandemic wave, as it was happening. Thus, this study provides explor-
atory impressions of what guidance development during the COVID-19
outbreak looked like, rather than seeking full data saturation.
To conclude, this study draws lessons about guidance develop-
ment during the COVID-19 crisis and points to the need to acknowl-
edge and communicate uncertainties of scientific evidence more
explicitly,13,24 by mobilizing important mechanisms that allow
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guidance developers to live with such uncertainty.25 Fostering these
mechanisms, especially those of strengthening pre- and post-
publication end-user involvement and more tightly conjoining evi-
dence review and recommendation formulation, may well prove
important contributions to extending guidance development
methods and processes more widely.
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ENDNOTES
* The development of clinical guidance, for example, generally takes
between 6 months up to 2 years.
† Policies on the use of face coverings are a telling example of the mis-
match between the high standards of evidence that warrant action and
the urgency of policy needs to act in a situation of uncertainty. At first,
the World Health Organization did not support the implementation of
face coverings in public, since the observed effect of facemasks was
classified as “low” certainty based on the GRADE framework. Evidence
on face coverings drawn from laboratory science, mathematical model-
ling and policy studies, for example, fail to generate a quantitative
estimate of effect size to support and legitimize policy action.26
Greenhalgh15 notes that the overuse of methodological quality as a cri-
terion for action is especially problematic in a setting in which the
assumptions of EBM cannot feasibly be met, nor is such evidence rele-
vant or desirable for the question at hand. Even the Cochrane Collabora-
tion published an article to underline the need to act on incomplete
evidence during the COVID-19 pandemic, noting that we may never
have strong evidence on public health interventions like individual
behavioural measures, nor are trials able to capture the effects of behav-
ioural measures “when deployed a general population living in the
complex, diverse circumstances of individuals' everyday lives” (see Ref-
erence [13], p. 1). In this setting, the authors note, “waiting for strong
evidence is a recipe for paralysis” (see Reference [13], p. 1).
‡ Incorporating the experiences and values by patients, professionals, and
citizens in COVID-19 guidance, given its high time pressure, may only
become possible through methodological innovation, for example through
deploying artificial intelligence for harvesting such experiences and value-
considerations. For first attempts at such inclusion of experience and
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